Anti-D Immunoglobulins Market Size, Trends & Forecast [2031]
Anti-D Immunoglobulins Market Size, Trends & Forecast [2031]
Segments - Anti-D Immunoglobulin Market by Dose Strength (100 mcg, 50 mcg, 300 mcg, and Others), by Packaging Type (Vials and Prefilled Syringe), and by Region (North America, Asia Pacific, Europe, Latin America, and the Middle East & Africa) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
Upcoming
| Report ID :HC-5969
| 4.8 Rating
| 64 Reviews
| 220 Pages
| Format :
Report Description
Anti-D Immunoglobulin Market Outlook 2031:
The global anti-D immunoglobulin market was estimated at USD 276.2 Million in 2022 and is anticipated to reach USD 497.9 Million by 2031, expanding at a CAGR of 7.0% during the forecast period.
Anti-D immunoglobulins are the antibodies that are given to treat Rh-negative pregnancies and immune thrombocytopenic purpura. Anti-D immunoglobulin injections neutralize the antibodies produced during the first pregnancy in the mother’s body. These antibodies form as a result of blood exchange from Rh-positive fetus and Rh-negative mother.
The neutralization of antibodies is very important, as the antibodies formed during the first pregnancy has the potential to harm the second pregnancy, which is the Rh-positive fetus. Anti-D immunoglobulins are given as a two-dose treatment, which are 28 – 34 weeks and the second dose is given within 72 hours of the baby delivery.
Macro-economic Factors
Government Regulations
Government regulations play an integral role in the approval and branding of anti-D immunoglobulins for the treatment of patients. The anti-D immunoglobulin injections come in various dose strength such as 100 mcg, 50 mcg, 300 mcg, and others.
The dose strengths are given to the patients based on their condition. Government bodies also regulate the pricing of these products. These regulatory authorities decide the ceiling price of the injections, which helps the patients to afford it during the required treatment time.
R&D Activities
Anti-D immunoglobulins are emerging as a significant class IgG antibodies for the treatment of Rh-negative mothers. The treatments available for the diseases are the outcome of previous R&D activities in the field of plasma products.
These R&D activities include various steps and perspectives consisting of participants, development phases, citations of related patents, and therapeutic indications with potentially valuable insights for pharmaceutical investors, researchers, and policymakers. R&D activities are a major factor affecting the overall Immunoglobulin market, as it allows the researchers to decide the appropriate concentration of drug that is required to be given to the patients.
Market Dynamics
Market Driver- Increasing Prevalence of Rh-negative Cases
Cases of Rh-negative pregnancies and hemolytic diseases are rising. In such complications, blood group is the major cause, as the probability of being Rh-negative mother and Rh-positive fetus is a very common fact. It is also be used for immune thrombocytopenic purpura, where the number of circulating platelets decrease, leading to easy bruising.
The injection nullifies the effect of antibodies formed during the Rh-positive blood transfusion in the patients. The transfusion takes place during childbirth, abortion, or any accident or intervention during pregnancy. This is expected to increase the use of anti-D immunoglobulin across the globe.
Market Driver- Advancements in the immunoglobulin delivery
Anti-D immunoglobulins are injected through intravenous route of administration. The traditional availability of anti-D immunoglobulins was in the vial form. In the recent years, the key players have introduced the prefilled syringes for the administration of anti-D immunoglobulins.
The prefilled syringes are advanced and effective way of administration, as the dose given to the patients is precise and safe. High income countries are adopting prefilled syringes for the administration of the medicine in Rh-negative mothers.
Market Restraint- Lack of awareness in underdeveloped countries
Anti-D immunoglobulins are popular in developed countries, as prenatal and post-natal care for the Rh-negative mothers. However, the anti-D immunoglobulins are not adopted in underdeveloped countries, due to lack of awareness, low disposable income of people, and lack of knowledge of Rh blood group conditions.
A major part of the global population resides in countries such as China and India; however, the primary consumption of Anti-D immunoglobulin is in North America and Europe. Lack of awareness regarding this is expected to affect the growth of the anti-D immunoglobulins market. Additionally, the availability of anti-D immunoglobulin is very low and at high cost in underdeveloped/developing countries.
Market Opportunity- Increasing Focus on R&D activities by manufacturers
Various companies and research institutes are investing in research and development of anti-D immunoglobulins as the major market is owned by very few players such as CSL Behring and Kedrion. This is expected to create lucrative opportunities for the market players.
Increasing number of pipeline products and development of novel treatments are anticipated to create immense opportunities for the market growth during the forecast period.
Scope of the Report
The report on the global anti-D immunoglobulins market includes an assessment of the market, size, share, trends, segments, and regional markets. Overview and dynamics have been included in the report.
|
Attributes |
Details |
|
Report Title |
Anti-D immunoglobulins Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
|
Base Year |
2022 |
|
Historic Data |
2016 and 2021 |
|
Forecast Period |
2023–2031 |
|
Segmentation |
By Dose Strength (100 mcg, 50 mcg, 300 mcg, Others), By Packaging Type (Vials, Prefilled Syringe) |
|
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and the Middle East & Africa |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
|
Key Players Covered |
BHARAT SERUMS AND VACCINES LIMITED, CSL Behring AG, Grifols, S.A., Octapharma AG, Kamada Pharmaceuticals, KEDRION SPA, OCEAN PHARMACEUTICAL, PV Pharma, Taj Pharmaceuticals Limited, and Zydus Group |
Anti-D Immunoglobulin Market Segmental Outlook
Based on dose strength, the anti-D immunoglobulins market is segmented into 100 mcg, 50 mcg, 300 mcg, and others. The 300 mcg segment accounts for a significant market share during the forecast period. 300 mcg and 50 mcg doses are the commonly prescribed doses for the patient’s condition during the prenatal and post-natal care.
These doses are widely available for the administration compared to the other forms such as 125 mcg and 250 mcg. These are major factors that are projected to boost the segment during the forecast period.
On the basis of packaging type, the anti-D immunoglobulins market is bifurcated into vials and prefilled syringes. The prefilled syringe segment is expected to expand at a significant CAGR during the forecast period, as the prefilled syringes are the convenient mode of drug administration over vials. The benefits of prefilled syringes include accurate dosing, reduced treatment time, and sterility while offering patients high choice, convenience, and ease-of-use.
Regional Outlook
The market is divided into five regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America is projected to account for a major share of the anti-D immunoglobulins market during the forecast period, owing to the rising number of FDA approvals for anti-D immunoglobulin injections and high awareness about these medication for the Rh-negative condition. North America has very high number of Rh-negative cases and the presence of multiple manufacturers makes the market very competitive.
Europe is expected to hold a substantial market share during the forecast period, owing to increasing R&D activities for prenatal and post-natal care of the Rh-negative cases.
The market in Asia Pacific is anticipated to expand at a high CAGR during the forecast period, as underdeveloped countries are adopting the anti-D immunoglobulin injections for treating the pregnancy complications. Significant rise in the Rh-negative pregnancy conditions is expected to boost the market in the coming years.
Key Developments
-
Kedrion is conducting surveys at a broad level to understand the clear picture of the Rh-negative incidence rate in China. The company is focusing on this region for their business expansion as the access to anti-D immunoglobulin is very limited.
-
On March 30, 2021; Kedrion launched Rh&Life clinical study. Rh&Life stands for Rhesus and Life (protection of life). This clinical study was initiated in 5 countries of Europe (Italy, Poland, Hungary, Czech Republic and Russia). The results of the study are expected to help the company to extend its product adoption rate in the Europe region.
Key Benefits for Industry Participants & Stakeholders
-
In-depth Analysis of the Global Anti-D Immunoglobulins Market
-
Historical, Current, and Projected Market Size in terms of Value
-
Potential & Niche Segments and Regions Exhibiting Promising Growth Covered
-
Industry Drivers, Restraints, and Opportunities Covered in the Study
-
Recent Industry Trends and Developments
-
Competitive Landscape & Strategies of Key Players
-
Neutral Perspective on Global Anti-D Immunoglobulins Market Performance
Segments
By Dose Strength
- 100 mcg
- 50 mcg
- 300 mcg
- Others
By Packaging Type
- Vial
- Prefilled Syringe
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Key Market Players Profiled in the Report
- BHARAT SERUMS AND VACCINES LIMITED
- CSL Behring AG
- Grifols, S.A.
- Octapharma AG
- Kamada Pharmaceuticals
- KEDRION SPA
- OCEAN PHARMACEUTICAL
- PV Pharma
- Taj Pharmaceuticals Limited
- Zydus Group
Competitive Landscape
-
Key players in the anti-D immunoglobulins market include BHARAT SERUMS AND VACCINES LIMITED, CSL Behring AG, Grifols, S.A., Octapharma AG, Kamada Pharmaceuticals, KEDRION SPA, OCEAN PHARMACEUTICAL, PV Pharma, Taj Pharmaceuticals Limited, and Zydus Group.
-
Market players are pursuing key strategies such as acquisitions, collaborations, and geographic expansion, which is creating opportunities in the anti-D immunoglobulins market.
Frequently Asked Questions
Additional company profiles are provided on request. For a discussion related to the above findings, click Speak to Analyst
Factors such as competitive strength and market positioning are key areas considered while selecting companies to be profiled.
Advancements in the immunoglobulin delivery and Increasing Prevalence of Rh-negative cases are driving the anti-D immunoglobulins market.
According to this Growth Market Reports report, the Anti-D immunoglobulins market is anticipated to register a CAGR of 7.0% during the forecast period, 2023-2031, with an anticipated valuation of USD 497.9 Million by the end of 2031.
300 mcg and 50 mcg are the major dose strength of anti-D immunoglobulins.
Factors such as government regulations and R&D activities are expected to act as macroeconomic factors for the market.
Major manufacturers include BHARAT SERUMS AND VACCINES LIMITED, CSL Behring AG, Grifols, S.A., Octapharma AG, Kamada Pharmaceuticals, KEDRION SPA, OCEAN PHARMACEUTICAL, PV Pharma, Taj Pharmaceuticals Limited, and Zydus Group.
Demand for and supply of anti-D immunoglobulins were slightly negatively affected during the pandemic, due to the scarcity of treatment processes.
In addition to market size (in USD Million), the company market share (in % for the base year 2022), impact of key regulations, latest trends in treatment method, overview, product innovation in anti-D immunoglobulins market, long-term market trends & opportunities, and scale of new market entrants are provided.
The base year considered for the global anti-D immunoglobulins market report is 2022. The complete analysis period is 2016 to 2031, wherein, 2016 and 2021 are the historic years, and the forecast is provided from 2023 to 2031.
Table Of Content
Chapter 1 Executive SummaryChapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Anti-D Immunoglobulin Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Anti-D Immunoglobulin Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Anti-D Immunoglobulin Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Anti-D Immunoglobulin Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Anti-D Immunoglobulin Market Size & Forecast, 2016-2031
4.5.1 Anti-D Immunoglobulin Market Size and Y-o-Y Growth
4.5.2 Anti-D Immunoglobulin Market Absolute $ Opportunity
4.6 Regulations & Compliances Associated with Anti-D Immunoglobulins
4.7 Recent Key Developments & Product Launches: Outlook
4.8 Supply vs Demand Gap Analysis: Anti-D Immunoglobulin Injections
Chapter 5 Global Anti-D Immunoglobulin Market Analysis and Forecast By Dose Strength
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities By Dose Strength
5.1.2 Basis Point Share (BPS) Analysis By Dose Strength
5.1.3 Absolute $ Opportunity Assessment By Dose Strength
5.2 Anti-D Immunoglobulin Market Size Forecast By Dose Strength
5.2.1 100 mcg
5.2.2 50 mcg
5.2.3 300 mcg
5.2.4 Others
5.3 Market Attractiveness Analysis By Dose Strength
Chapter 6 Global Anti-D Immunoglobulin Market Analysis and Forecast By Packaging Type
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities By Packaging Type
6.1.2 Basis Point Share (BPS) Analysis By Packaging Type
6.1.3 Absolute $ Opportunity Assessment By Packaging Type
6.2 Anti-D Immunoglobulin Market Size Forecast By Packaging Type
6.2.1 Vial
6.2.2 Prefilled Syringe
6.3 Market Attractiveness Analysis By Packaging Type
Chapter 7 Global Anti-D Immunoglobulin Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Anti-D Immunoglobulin Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Anti-D Immunoglobulin Analysis and Forecast
9.1 Introduction
9.2 North America Anti-D Immunoglobulin Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Anti-D Immunoglobulin Market Size Forecast By Dose Strength
9.6.1 100 mcg
9.6.2 50 mcg
9.6.3 300 mcg
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis By Dose Strength
9.8 Absolute $ Opportunity Assessment By Dose Strength
9.9 Market Attractiveness Analysis By Dose Strength
9.10 North America Anti-D Immunoglobulin Market Size Forecast By Packaging Type
9.10.1 Vial
9.10.2 Prefilled Syringe
9.11 Basis Point Share (BPS) Analysis By Packaging Type
9.12 Absolute $ Opportunity Assessment By Packaging Type
9.13 Market Attractiveness Analysis By Packaging Type
Chapter 10 Europe Anti-D Immunoglobulin Analysis and Forecast
10.1 Introduction
10.2 Europe Anti-D Immunoglobulin Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Anti-D Immunoglobulin Market Size Forecast By Dose Strength
10.6.1 100 mcg
10.6.2 50 mcg
10.6.3 300 mcg
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis By Dose Strength
10.8 Absolute $ Opportunity Assessment By Dose Strength
10.9 Market Attractiveness Analysis By Dose Strength
10.10 Europe Anti-D Immunoglobulin Market Size Forecast By Packaging Type
10.10.1 Vial
10.10.2 Prefilled Syringe
10.11 Basis Point Share (BPS) Analysis By Packaging Type
10.12 Absolute $ Opportunity Assessment By Packaging Type
10.13 Market Attractiveness Analysis By Packaging Type
Chapter 11 Asia Pacific Anti-D Immunoglobulin Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Anti-D Immunoglobulin Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Anti-D Immunoglobulin Market Size Forecast By Dose Strength
11.6.1 100 mcg
11.6.2 50 mcg
11.6.3 300 mcg
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis By Dose Strength
11.8 Absolute $ Opportunity Assessment By Dose Strength
11.9 Market Attractiveness Analysis By Dose Strength
11.10 Asia Pacific Anti-D Immunoglobulin Market Size Forecast By Packaging Type
11.10.1 Vial
11.10.2 Prefilled Syringe
11.11 Basis Point Share (BPS) Analysis By Packaging Type
11.12 Absolute $ Opportunity Assessment By Packaging Type
11.13 Market Attractiveness Analysis By Packaging Type
Chapter 12 Latin America Anti-D Immunoglobulin Analysis and Forecast
12.1 Introduction
12.2 Latin America Anti-D Immunoglobulin Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Anti-D Immunoglobulin Market Size Forecast By Dose Strength
12.6.1 100 mcg
12.6.2 50 mcg
12.6.3 300 mcg
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis By Dose Strength
12.8 Absolute $ Opportunity Assessment By Dose Strength
12.9 Market Attractiveness Analysis By Dose Strength
12.10 Latin America Anti-D Immunoglobulin Market Size Forecast By Packaging Type
12.10.1 Vial
12.10.2 Prefilled Syringe
12.11 Basis Point Share (BPS) Analysis By Packaging Type
12.12 Absolute $ Opportunity Assessment By Packaging Type
12.13 Market Attractiveness Analysis By Packaging Type
Chapter 13 Middle East & Africa (MEA) Anti-D Immunoglobulin Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Anti-D Immunoglobulin Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Anti-D Immunoglobulin Market Size Forecast By Dose Strength
13.6.1 100 mcg
13.6.2 50 mcg
13.6.3 300 mcg
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis By Dose Strength
13.8 Absolute $ Opportunity Assessment By Dose Strength
13.9 Market Attractiveness Analysis By Dose Strength
13.10 Middle East & Africa (MEA) Anti-D Immunoglobulin Market Size Forecast By Packaging Type
13.10.1 Vial
13.10.2 Prefilled Syringe
13.11 Basis Point Share (BPS) Analysis By Packaging Type
13.12 Absolute $ Opportunity Assessment By Packaging Type
13.13 Market Attractiveness Analysis By Packaging Type
Chapter 14 Competition Landscape
14.1 Anti-D Immunoglobulin Market: Competitive Dashboard
14.2 Global Anti-D Immunoglobulin Market: Market Share Analysis, 2022
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 BHARAT SERUMS AND VACCINES LIMITED
14.3.2 CSL Behring AG
14.3.3 Grifols, S.A.
14.3.4 Octapharma AG
14.3.5 Kamada Pharmaceuticals
14.3.6 KEDRION SPA
14.3.7 OCEAN PHARMACEUTICAL
14.3.8 PV Pharma
14.3.9 Taj Pharmaceuticals Limited
14.3.10 Zydus Group
Methodology
Related Reports
Some other reports from this category!
Our Clients
